Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.
Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Product Categories
Product Type
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

VZ 185 is a proteolysis-targeting chimera (PROTAC) composed of a von Hippel-Lindau (VHL) ligand and bromodomain-containing protein 7 (BRD7)- and BRD9-binding ligand.1 It is selective for BRD7 and BRD9 over 6,273 other proteins at 100 nM. VZ 185 degrades BRD7 and BRD9 with half-maximal degradation concentration (DC50) values of 4.5 and 1.8 nM, respectively, in a cell-free assay. It decreases BRD7 and BRD9 levels in HeLa cells by 10 and 14%, respectively, when used at a concentration of 1 µM. VZ 185 reduces the proliferation of EoL-1 leukemia and A-204 sarcoma cells (IC50s = 3.4 and 39 nM, respectively).
WARNING This product is not for human or veterinary use.
1. Iterative design and optimization of initially inactive proteolysis targeting chimeras (PROTACs) identify VZ185 as a potent, fast, and selective von hippel-